Celsion Corporation (NASDAQ:CLSN) headquartered in Lawrenceville, will host a conference call for the investment community to discuss the 3Q20 earnings result on 16th November 2020 at 11:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.celsion.com
Individuals interested in participating in the audio call may dial the listen only number(s) 1-800-367-2403 Toll Free, (United States) or 1-334-777-6978 (International), with passcode : 8337630
Earnings Expectation
Celsion Corporation is reporting third quarter financial results on Monday 16th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, CLSN is expected to report 3Q20 loss of $ 0.13 per share from revenue of $ 0.08 million.
For the full year, analysts anticipate top line of $ 0.38 million, while looking forward to loss of $ 0.63 per share bottom line.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.
